Biovest presenting at major immunotherapy forum
Biovest International, the immunotherapy biotech, will be making a presentation at the upcoming Immunotherapy Leaders' Forum 2012, taking place at the Fira Palace in Barcelona, Spain between May 9 and May 11.
There, Carlos F. Santos, Ph.D., Biovest’s Senior Vice President, Product Development & Regulatory Affairs, will present and participate in multiple panel sessions and discussing the Company’s late-stage personalized cancer vaccine for non-Hodgkin’s lymphoma, BiovaxID.
Biovest was recently in the news for their meetings with regulatory officials in Canada about getting their personalized cancer vaccine on the market in that country, as well as an upcoming presentation by the National Cancer Institute to attendees of the American Society of Clinical Oncology's annual meeting in June. There, representatives will discuss trial data supporting BiovaxID against mantle cell lymphoma.
For more information on the Leaders' Forum, click here
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
